Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2024-09-30 M&A Activity
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)
M&A Activity Classification · 1% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' detailing a strategic decision by Xlife Sciences AG to pursue a dual listing on the London Stock Exchange Group (LSEG) to increase market capitalization and liquidity. This type of announcement, which discloses material, non-public information regarding strategic corporate actions (like listing plans or major strategic shifts) outside of routine periodic filings, is typically classified as a general regulatory announcement or 'Inside Information'. Since the provided definitions do not have a specific code for 'Ad hoc announcement' or 'Inside Information', and the document is not a specific report (like 10-K, IR, ER) but rather a disclosure of a major corporate event, the most appropriate fallback category is 'Regulatory Filings' (RNS). The document length (3008 chars) is short, but it is the primary disclosure, not an announcement *about* another report, so RPA is not applicable. It is not about management changes (MANG), director dealings (DIRS), or capital changes (CAP) in the sense of issuing shares, but a strategic listing plan.
2024-09-30 English
Xlife Sciences AG ermöglicht internationalen Co-Investoren den Einstieg in die Aktie und plant hierfür ein Dual Listing an der Londoner Stock Exchange Group (LSEG)
Regulatory Filings Classification · 1% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and is published by Xlife Sciences AG. It announces a strategic decision: planning a Dual Listing on the London Stock Exchange Group (LSEG) to increase market capitalization and liquidity, in cooperation with new international co-investors. This type of immediate, material, non-scheduled corporate news release, especially one originating from a European regulatory context (indicated by 'Ad hoc-Mitteilung' and 'KR'), typically falls under general regulatory announcements or miscellaneous filings that don't fit specific financial report categories. Since it is a mandatory disclosure of a significant corporate event that isn't a standard financial report (10-K, IR, ER) or a specific corporate action like a dividend or share buyback, the most appropriate general category is Regulatory Filings (RNS). The document length (4582 chars) is short enough that it might be considered an announcement, but the content is the core news itself, not just an announcement *of* an attached report, making RNS more suitable than RPA.
2024-09-30 German
Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and Solid Financial Figures
Earnings Release Classification · 1% confidence The document explicitly states it is the '2024 Half-Year Report' and announces 'Key word(s): Half Year Results/Interim Report'. It provides key financial figures (revenue, EPS, balance sheet total) for the first half of 2024 and directs the reader to download the full report. According to the definitions, a comprehensive financial report for a period shorter than a year is classified as an Interim / Quarterly Report (IR). Although it mentions the report is published, the content provided is substantial enough (summarizing results and operational highlights) that it functions as the primary announcement of the interim results, rather than just a brief RPA pointing to the full document. However, since the text explicitly states the full report is available for download and this is an 'Ad hoc announcement pursuant to Art. 53 LR' (often a brief regulatory disclosure), it leans towards being an announcement of the report's availability. Given the detailed financial summary included, it is a hybrid, but the core subject is the release of the Half-Year Report. The closest specific category for a comprehensive report covering a period shorter than a year is 'IR'. If it were purely a short notice saying 'The IR is attached', RPA would be better. Since it contains the key figures and operational highlights, IR is the most appropriate classification for the content being summarized, even if it's technically an announcement of the full document's release. H1 2024
2024-09-19 English
Xlife Sciences AG: Erfolgreiches erstes Halbjahr 2024 mit strategischen Fortschritten und soliden Finanzkennzahlen
Earnings Release Classification · 1% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and explicitly states that the company 'hat heute ihren Halbjahresbericht 2024 veröffentlicht' (has published its Half-Year Report 2024 today). It provides key financial highlights (Umsatzerlös, Ergebnis je Aktie, Bilanzsumme) for the first half of 2024 and operational updates. This structure—an announcement summarizing results for a period shorter than a year—fits the definition of an Interim/Quarterly Report (IR). However, the document itself is an 'Ad hoc-Mitteilung' (a regulatory disclosure) announcing the publication of the full report, which is available via a link. According to Rule 2 (The 'MENU VS MEAL' Rule), if the document is short and announces that a report has been published, it should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is a specific announcement about the release of a financial report (Halbjahresbericht), RPA is the most precise fit, as it signals the publication event rather than being the comprehensive report itself. The content strongly suggests an announcement of results, which aligns with the function of an RPA. H1 2024
2024-09-19 German
Xlife Sciences AG Completes Strategic Review Process by Q3 2024
Regulatory Filings Classification · 1% confidence The document is a short announcement dated September 3, 2024, released as an 'Ad-hoc announcement pursuant to Art. 53 LR'. It discusses the completion of a strategic review process and informs shareholders about next steps. Crucially, it contains a 'Financial calendar' section which explicitly states: 'Half-Year Report 2024 | 19 September 2024'. Since the document itself is short (2623 chars) and its primary function is to communicate a corporate event (completion of a review) while also announcing the future publication date of a major report (Half-Year Report), it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is an ad-hoc announcement about a strategic milestone and future reporting schedule, and not the report itself, RPA is the most specific fit among the announcement types, as it relates directly to the publication of financial information (the Half-Year Report). However, since the core content is a strategic update rather than just announcing the report, and it is an 'Ad-hoc' release, RNS (Regulatory Filings - general regulatory announcements) is also a strong candidate. Comparing RPA (announcement regarding the timing, release, or publication of company reports) and RNS (general regulatory announcements/fallback), this document is primarily a strategic update that happens to mention a future report date. In many jurisdictions, such ad-hoc strategic updates fall under general regulatory disclosure rules. Given the presence of the financial calendar, RPA is highly relevant. I will select RPA as it specifically mentions the publication of a future report, aligning with the RPA definition, even though it contains other strategic news.
2024-09-03 English
Xlife Sciences AG Completes Strategic Review Process by Q3 2024
Report Publication Announcement Classification · 1% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' from Xlife Sciences AG, dated September 3, 2024. It announces the completion of a strategic review process and informs stakeholders about the next steps and timeline. It is a brief, unscheduled corporate disclosure regarding internal strategy implementation, not a full financial report (like 10-K or IR), a specific transaction (like DIV or POS), or a management change (MANG). Since it is a general, unscheduled regulatory disclosure that doesn't fit the highly specific categories like DIRS, DVA, or CAP, it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings). The document length is short (2440 chars) and it is an announcement, not the detailed report itself.
2024-09-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.